

EIGHTH EDITION NOW AVAILABLE!

The Precision Oncology Annual Trend Report

Perspectives From Oncologists, Pathologists, and Payers

As part of the ongoing Novartis commitment, **The Precision Oncology Annual Trend Report: Perspectives From Oncologists, Pathologists, and Payers, Eighth Edition**, offers insights into the trending topics and discoveries taking place in the evolving field of precision oncology.*




Oncologist respondents report that the molecular pathology report is as important as peer-reviewed journals as sources of information influencing their use of targeted therapies.

Did you know?

- The number of oncologists utilizing **liquid biopsy in NSCLC** increased from 50% in 2020 to 83% in 2021, **an increase of 66%**
- The number of oncologists utilizing **PDGFRB in MDS** increased from 49% in 2020 to 86% in 2021, **an increase of 76%**
- Coverage of **HER2 in esophago-gastric adenocarcinoma** increased from 88% in 2020 to 98% in 2021, **an increase of 11%**
- Coverage of **PD-L1 in melanoma** increased from 78% in 2020 to 92% in 2021, **an increase of 18%**

Highlights

Oncologists and payers report significant changes in factors impacting utilization and/or coverage decisions for new targeted therapy†



N=50 oncologists, 60 payers.

NA, not asked.

Values in parentheses indicate a statistically significant percent change from 2020.

Q1. When making <coverage/utilization> decisions for new targeted therapies, please rate the importance of the following attributes on a scale from 1-7. FDA, US Food and Drug Administration; MDS, myelodysplastic syndrome; NCCN, National Comprehensive Cancer Network®; NSCLC, non-small cell lung cancer.

*Market research results commissioned by Novartis that shed light on the evolution, dynamics, and trends impacting precision oncology.

The 2021 survey included 50 oncologists, 30 pathologists, and 60 payers.

†Topic areas included represent statistically significant changes in 2021.


‡Reproduced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®)

© 2021 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Accessed April 27, 2022.

To view the most recent and complete version of the NCCN Compendium®, go online to NCCN.org.

Highlights (continued)

NCCN is the most frequently used information source for biomarker test utilization and coverage decisions




N=50 oncologists, 30 pathologists, 60 payers.

Values in parentheses indicate a statistically significant percent change from 2020.

Q8. When using third parties to guide your <coverage/utilization> decisions for oncology predictive biomarkers, please rate the following statements on a scale from 1-7.

Oncologists indicate that the molecular pathology report is a leading information source in treatment decisions for new targeted therapies




N=50 oncologists.

Values in parentheses indicate a statistically significant percent change from 2020.

Q2. When making <coverage/utilization> decisions for new targeted therapies, please rate the importance of the following sources of information on a scale from 1-7.

The Precision Oncology Annual Trend Report continues to bring to light developing trends and how they impact the important decisions being made to adopt and utilize precision oncology.

For a copy of *The Precision Oncology Annual Trend Report*, contact your Novartis representative or visit hcp.novartis.com/care-management.



*Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium[®]) © 2021 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Accessed April 27, 2022. To view the most recent and complete version of the NCCN Compendium[®], go online to NCCN.org.

†Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Reference: Novartis Oncology. *The Precision Oncology Annual Trend Report: Perspectives From Oncologists, Pathologists, and Payers*. 8th ed; 2022.

